Growth Modulation in the Treatment of Idiopathic Scoliosis Using the REFLECT™ Scoliosis Correction System

Overview

Información sobre este estudio

The purpose of this multi-center, prospective, single-arm registry Post-Approval Study (PAS) is to evaluate the radiographic and clinical outcomes of 100 patients with idiopathic scoliosis treated with the REFLECT™ Scoliosis Correction System, as a condition of HDE approval.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Diagnosis of progressive idiopathic scoliosis.
  • Preoperative major Cobb angle 30°-65°.
  • Preoperative flexibility to ≤ 30° on side bending radiograph (left or right).
  • Skeletally immature at the time of surgery with Risser sign < 5 or Sanders score < 8.
  • Osseous structure dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging.
  • Failed or intolerant to bracing.
  • Signed informed consent and/or assent forms specific to this study.

Exclusion Criteria:

  • Prior spinal surgery at the level(s) to be treated.
  • Documented poor bone quality, defined as a T-score of -1.5 or less.
  • Presence of any systemic infection, local infection, or skin compromise at the surgical site P.
  • Any medical or surgical condition which would preclude the potential benefit of spinal surgery, such as coagulation disorders, allergies to the implant materials, and patient's unwillingness or inability to cooperate with post-operative care instructions.
  • Unwillingness, inability, or living situation (e.g. custody arrangements, homelessness, detention) that would preclude ability to return to the study site for follow-up visits as described in protocol and Informed Consent.
  • Active participation in a drug or device study that is more than minimal risk such that participation would confound the measurements of the present study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/11/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Annalise Larson, M.D.

Abierto para la inscripción

Contact information:

Angela Severson

(507) 538-3560

Severson.Angela2@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20562144

Mayo Clinic Footer